Show simple item record

dc.contributor.authorChimondeguy, Domingo.
dc.contributor.authorArboit, David.
dc.contributor.authorBuero, Agustín.
dc.contributor.authorEt al.
dc.date.accessioned2023-10-09T15:07:39Z
dc.date.available2023-10-09T15:07:39Z
dc.date.issued2021-11
dc.identifier.citationEcancermedicalscience . 2021 Nov 25:15:1322es
dc.identifier.issn1754-6605
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/2312
dc.descriptionDisponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723740/pdf/can-15-1322.pdfes
dc.description.abstractAbstract Objective: Long-term survival of patients who undergo surgical resection of isolated adrenal metastasis instead of nonsurgical treatment has shown higher values than those described for stage IVA. The primary endpoint was to evaluate overall survival (OS) of patients with single adrenal metastasis from non-small cell lung cancer (NSCLC), who underwent surgical treatment. The secondary endpoint was to evaluate and compare the OS and disease-free survival (DFS) according to: pathological lung tumour size, histology, lymph node involvement, type of metastasis at the time of diagnosis and laterality of the metastasis according to the primary lung tumour. Methods: From August 2007 to March 2020, 13 patients with isolated adrenal gland metastasis were identified. We performed a descriptive observational study including patients with diagnosed single adrenal gland metastasis of resectable primary lung cancer and no history of other malignant disease. Clinical data obtained included patient demographics, metastases characteristics, laterality of the metastasis, time between surgeries, length of follow-up, survival status, pathological lung tumour size, histology and lymph node involvement. The variables analysed were OS and DFS. Results: Median global OS was 31.9 months (interquartile range (IQR), 19.1-51.4). The 2- and 5-year OS estimated was 54% (95% CI: 29.5%-77.4%) and 36% (95% CI: 13.4%-68.1%), respectively. In patients with NSCLC without mediastinal lymph node involvement, we obtain a median OS of 40 months (IQR, 27.4-51.4) and a 2- and 5-year OS estimated of 75% (95% CI: 43.2%-92.2%) and 50% (95% CI: 18.7%-81.2%), respectively. Recurrence was detected in five patients with a median DFS of 11.9 months (IQR, 6-34.2). Conclusion: The resection of the adrenal metastasis should be considered if the primary lung cancer is resectable. Presence of mediastinal lymph node involvement should be ruled out through invasive staging of the mediastinum before performing adrenal and lung surgery. Proper selection of patients who would benefit from surgery is essential to obtain better survival results. Keywords: adrenal metastasis; adrenalectomy; non-small cell lung cancer; oligometastasis. © the authors; licensee ecancermedicalscience.es
dc.language.isoenes
dc.publisherEcancermedicalsciencees
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAdrenal metastasises
dc.subjectAdrenalectomyes
dc.subjectNon-small cell lung canceres
dc.titleOutcomes of surgical treatment for isolated adrenal metastasis from non-small cell lung canceres
dc.typeArticlees


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional